{"filing":{"accession_number":"0001099800-26-000038","cik":"0001099800","ticker":"EW","company_name":"Edwards Lifesciences Corp","form":"8-K","filing_date":"2026-07-23","report_date":null,"primary_document":"ew-20260723.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1099800/000109980026000038/ew-20260723.htm"},"events":[{"id":20114,"run_id":18105,"accession_number":"0001099800-26-000038","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.99,"summary":"Edwards Lifesciences issued a press release on July 23, 2026 disclosing second quarter 2026 financial results, including Q2 sales of $1.74 billion (13.6% growth), Q2 EPS of $0.42 (adjusted $0.78), and updated 2026 full-year guidance. The filing is structured as Item 2.02 with the press release furnished as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes detailed segment performance (TAVR, TMTT, Surgical), margin analysis, and forward guidance.","company_name":"Edwards Lifesciences Corp","ticker":"EW","filing_date":"2026-07-23","form":"8-K","submitted_at":null,"items":[{"id":19390,"accession_number":"0001099800-26-000038","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.99,"reasoning":"Edwards Lifesciences issued a press release on July 23, 2026 disclosing second quarter 2026 financial results, including Q2 sales of $1.74 billion (13.6% growth), Q2 EPS of $0.42 (adjusted $0.78), and updated 2026 full-year guidance. The filing is structured as Item 2.02 with the press release furnished as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes detailed segment performance (TAVR, TMTT, Surgical), margin analysis, and forward guidance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-23T20:29:49.676028+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":19390,"accession_number":"0001099800-26-000038","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.99,"reasoning":"Edwards Lifesciences issued a press release on July 23, 2026 disclosing second quarter 2026 financial results, including Q2 sales of $1.74 billion (13.6% growth), Q2 EPS of $0.42 (adjusted $0.78), and updated 2026 full-year guidance. The filing is structured as Item 2.02 with the press release furnished as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes detailed segment performance (TAVR, TMTT, Surgical), margin analysis, and forward guidance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-23T20:29:49.676028+00:00","company_name":"Edwards Lifesciences Corp","ticker":"EW","filing_date":"2026-07-23"}]}